Drugs / NS-136
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06345703 | Apr → Nov 2024 overdue | — | NeuShen Therapeutics | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07521683 | Oct 2025 → Nov 2026 expected | schizophrenia | NeuShen Therapeutics | Enrolling by invitation | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-01-02 | NeuShen Therapeutics | Regulatory NeuShen Therapeutics Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NS-136 in Agitation in Alzheimer’s Disease (AAD) neushen.com ↗
FDA’s clearance to initiate Phase 2 study of NS-136 is a significant milestone for NeuShen and a testament to our R&D capabilities. |
| 2025-09-28 | NeuShen Therapeutics | Results NeuShen Therapeutics to Present at Neuroscience 2025 neushen.com ↗
In a completed Phase 1 clinical trial on healthy subjects (including both adults and elderly individuals), NS-136 exhibited an excellent safety and pharmacokinetic profile. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-02 | NeuShen Therapeutics | NeuShen Therapeutics Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NS-136 in Agitation in Alzheimer’s Disease (AAD) neushen.com ↗ |
| 2025-11-19 | NeuShen Therapeutics | NeuShen Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of NS-136 for Schizophrenia neushen.com ↗ |
| 2025-09-28 | NeuShen Therapeutics | NeuShen Therapeutics to Present at Neuroscience 2025 neushen.com ↗ |
| 2024-04-30 | NeuShen Therapeutics | NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia neushen.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NS-136 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06345703 ↗ |